Literature DB >> 20065079

Genetic lesions in chronic lymphocytic leukemia: what's ready for prime time use?

Carol Moreno, Emili Montserrat.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20065079      PMCID： PMC2805746          DOI： 10.3324/haematol.2009.016873

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  30 in total

1.  Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia.

Authors:  Gerard Tobin; Ulf Thunberg; Anna Johnson; Ingrid Thörn; Ola Söderberg; Magnus Hultdin; Johan Botling; Gunilla Enblad; Jan Sällström; Christer Sundström; Göran Roos; Richard Rosenquist
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

2.  ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.

Authors:  Laura Z Rassenti; Lang Huynh; Tracy L Toy; Liguang Chen; Michael J Keating; John G Gribben; Donna S Neuberg; Ian W Flinn; Kanti R Rai; John C Byrd; Neil E Kay; Andrew Greaves; Arthur Weiss; Thomas J Kipps
Journal:  N Engl J Med       Date:  2004-08-26       Impact factor: 91.245

3.  Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia.

Authors:  Dirk Kienle; Axel Benner; Carolin Läufle; Dirk Winkler; Christof Schneider; Andreas Bühler; Thorsten Zenz; Annett Habermann; Ulrich Jäger; Peter Lichter; Riccardo Dalla-Favera; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

4.  Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival.

Authors:  J R Neilson; R Auer; D White; N Bienz; J J Waters; J A Whittaker; D W Milligan; C D Fegan
Journal:  Leukemia       Date:  1997-11       Impact factor: 11.528

5.  Genomic aberrations and survival in chronic lymphocytic leukemia.

Authors:  H Döhner; S Stilgenbauer; A Benner; E Leupolt; A Kröber; L Bullinger; K Döhner; M Bentz; P Lichter
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

6.  ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

Authors:  Marta Crespo; Francesc Bosch; Neus Villamor; Beatriz Bellosillo; Dolors Colomer; María Rozman; Silvia Marcé; Armando López-Guillermo; Elies Campo; Emili Montserrat
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

7.  Karyotype-specific microRNA signature in chronic lymphocytic leukemia.

Authors:  Rosa Visone; Laura Z Rassenti; Angelo Veronese; Cristian Taccioli; Stefan Costinean; Baltazar D Aguda; Stefano Volinia; Manuela Ferracin; Jeff Palatini; Veronica Balatti; Hansjuerg Alder; Massimo Negrini; Thomas J Kipps; Carlo M Croce
Journal:  Blood       Date:  2009-08-28       Impact factor: 22.113

8.  Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition.

Authors:  Jianguo Zhuang; Stephen F Hawkins; Mark A Glenn; Ke Lin; Gillian G Johnson; Anthony Carter; John C Cawley; Andrew R Pettitt
Journal:  Haematologica       Date:  2009-08-27       Impact factor: 9.941

9.  A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia.

Authors:  Daphne R Friedman; J Brice Weinberg; William T Barry; Barbara K Goodman; Alicia D Volkheimer; Karen M Bond; Youwei Chen; Ning Jiang; Joseph O Moore; Jon P Gockerman; Louis F Diehl; Carlos M Decastro; Anil Potti; Joseph R Nevins
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

10.  MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias.

Authors:  George Adrian Calin; Chang-Gong Liu; Cinzia Sevignani; Manuela Ferracin; Nadia Felli; Calin Dan Dumitru; Masayoshi Shimizu; Amelia Cimmino; Simona Zupo; Mariella Dono; Marie L Dell'Aquila; Hansjuerg Alder; Laura Rassenti; Thomas J Kipps; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-29       Impact factor: 11.205
View more
  6 in total

Review 1.  miR deregulation in CLL.

Authors:  Veronica Balatti; Yuri Pekarky; Lara Rizzotto; Carlo M Croce
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

2.  De novo deletion 17p13.1 as a predictor for disease progression in chronic lymphocytic leukemia.

Authors:  Amro M S El-Ghammaz; Essam Abdelwahed; Nevine N Mostafa; Dina A Mansour
Journal:  Clin Exp Med       Date:  2014-10-10       Impact factor: 3.984

3.  Novel mechanisms of regulation of miRNAs in CLL.

Authors:  Veronica Balatti; Mario Acunzo; Yuri Pekarky; Carlo M Croce
Journal:  Trends Cancer       Date:  2016-03

4.  TACI expression and signaling in chronic lymphocytic leukemia.

Authors:  Antigoni Mamara; Anastasios E Germenis; Maria Kompoti; Maria Palassopoulou; Eudokia Mandala; Anastasia Banti; Nikolaos Giannakoulas; Matthaios Speletas
Journal:  J Immunol Res       Date:  2015-04-09       Impact factor: 4.818

Review 5.  Role of microRNA in chronic lymphocytic leukemia onset and progression.

Authors:  Veronica Balatti; Yuri Pekarky; Carlo M Croce
Journal:  J Hematol Oncol       Date:  2015-02-20       Impact factor: 17.388

6.  Relationship between Chromosomal Aberrations and Gene Expressions in the p53 Pathway in Chronic Lymphocytic Leukemia.

Authors:  G Öztan; M Aktan; S Palanduz; H İşsever; S Öztürk; E Nikerel; A Uçur; G Bağatir; A Bayrak; K Çefle
Journal:  Balkan J Med Genet       Date:  2020-08-26       Impact factor: 0.519
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.